Hot Investor Mandate 6: Global Pharma Firm Invests in Small Molecules and Biologics in Cardiology, Immunology, CNS, And More

19 Oct

A global pharmaceutical company based in Europe forms in-licensing and partnering relationships with early stage therapeutic companies worldwide. The firm also has a corporate venture group which makes equity investments in early stage companies.

The firm’s focus areas are Cardiometabolic disease, CNS, Immunology, Oncology, and Respiratory diseases. Therapeutic opportunities beyond these focus areas may be considered by the corporate venture fund or by an internal research group, which assesses very early-stage emerging areas of science. The firm considers both small molecule and biologic assets but is generally not interested in cell therapy technologies. The firm prefers to consider assets that have attained proof of concept data (in vitro or in vivo) linking the treatment’s mechanism of action to the disease process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: